Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-04-07 Sale | 2025-04-09 4:25 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $18.04 | $120,269 | 316,643 (Indirect) | View |
| 2025-03-27 Sale | 2025-03-31 7:37 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $21.33 | $69,321 | 151,556 (Direct) | View |
| 2025-03-24 Sale | 2025-03-26 7:37 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $22.5 | $22,505 | 154,806 (Direct) | View |
| 2025-03-19 Sale | 2025-03-21 5:49 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $20.61 | $257,575 | 1,002,688 (Indirect) | View |
| 2025-03-17 Sale | 2025-03-19 5:42 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $20.83 | $260,320 | 990,392 (Indirect) | View |
| 2025-03-07 Sale | 2025-03-11 5:18 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $21.44 | $142,936 | 323,310 (Indirect) | View |
| 2025-02-27 Sale | 2025-03-03 8:07 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.41 | $66,327 | 155,806 (Direct) | View |
| 2025-02-07 Sale | 2025-02-10 5:32 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $21.93 | $146,206 | 500,977 (Indirect Direct) | View |
| 2025-02-05 Sale | 2025-02-07 7:06 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $22.52 | $22,524 | 159,056 (Direct) | View |
| 2025-01-27 Sale | 2025-01-29 7:21 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $21.59 | $70,178 | 160,056 (Direct) | View |
| 2025-01-07 Sale | 2025-01-10 5:31 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 28,367 | $24.18 | $685,868 | 381,880 (Indirect Direct) | View |
| 2025-01-03 Sale | 2025-01-07 4:43 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $25.04 | $25,039 | 318,862 (Direct) | View |
| 2024-12-27 Sale | 2024-12-31 5:18 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $22.23 | $94,474 | 329,512 (Direct) | View |
| 2024-11-27 Sale | 2024-12-02 5:18 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $24.89 | $130,688 | 168,556 (Direct) | View |
| 2024-10-28 Sale | 2024-10-30 6:04 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $28.56 | $178,485 | 173,806 (Direct) | View |
| 2024-10-18 Sale | 2024-10-22 4:23 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 716 | $30 | $21,483 | 343,311 (Indirect) | View |
| 2024-10-18 Sale | 2024-10-22 4:22 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 847 | $30 | $25,413 | 1,015,188 (Indirect) | View |
| 2024-10-18 Sale | 2024-10-22 4:21 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 924 | $30 | $27,723 | 1,002,892 (Indirect) | View |
| 2024-10-18 Sale | 2024-10-22 4:19 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 814 | $30 | $24,422 | 180,056 (Direct) | View |
| 2024-10-18 Sale | 2024-10-22 4:18 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,570 | $30 | $47,104 | 188,245 (Indirect Direct) | View |
| 2024-10-18 Sale | 2024-10-22 4:17 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $30 | $24,482 | 266,268 (Direct) | View |
| 2024-10-15 Sale | 2024-10-17 5:06 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $27.67 | $35,143 | 189,815 (Indirect Direct) | View |
| 2024-10-08 Sale | 2024-10-10 8:39 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 51,145 | $28.11 | $1,437,585 | 1,016,035 (Indirect) | View |
| 2024-10-08 Sale | 2024-10-10 8:38 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 29,977 | $28.07 | $841,334 | 1,003,816 (Indirect) | View |
| 2024-10-08 Sale | 2024-10-10 8:36 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 10,420 | $28.17 | $293,557 | 104,091 (Direct) | View |
| 2024-10-04 Sale | 2024-10-08 6:58 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 10,229 | $27.54 | $281,664 | 1,067,180 (Indirect) | View |
| 2024-10-04 Sale | 2024-10-08 6:57 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 14,936 | $27.51 | $410,867 | 1,033,793 (Indirect) | View |
| 2024-10-04 Sale | 2024-10-08 6:56 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 11,488 | $27.51 | $316,014 | 363,010 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-03-27 Exercise | 2025-03-31 7:37 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 151,556 (Direct) | View |
| 2025-03-27 Exercise | 2025-03-31 7:37 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 151,556 (Direct) | View |
| 2025-03-24 Exercise | 2025-03-26 7:37 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $0 | 154,806 (Direct) | View |
| 2025-03-24 Exercise | 2025-03-26 7:37 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $2.48 | 154,806 (Direct) | View |
| 2025-03-04 Exercise | 2025-03-06 6:02 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 10,000 | $0 | 155,806 (Direct) | View |
| 2025-03-04 Exercise | 2025-03-06 6:02 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 10,000 | $2.48 | 155,806 (Direct) | View |
| 2025-02-27 Exercise | 2025-03-03 8:07 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 155,806 (Direct) | View |
| 2025-02-27 Exercise | 2025-03-03 8:07 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 155,806 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:40 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director | 20,491 | $0 | 20,491 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:39 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 15,368 | $0 | 15,368 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:38 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 23,014 | $0 | 23,014 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:36 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 20,491 | $0 | 20,491 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:35 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 20,491 | $0 | 20,491 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:34 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 20,491 | $0 | 20,491 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:33 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 20,491 | $0 | 20,491 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:32 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 171,000 | $0 | 500,977 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:29 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 171,000 | $0 | 171,000 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:28 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 490,000 | $0 | 490,000 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:27 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 171,000 | $0 | 171,000 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:25 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 171,000 | $0 | 171,000 (Direct) | View |
| 2025-02-05 Exercise | 2025-02-07 7:06 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $0 | 159,056 (Direct) | View |
| 2025-02-05 Exercise | 2025-02-07 7:06 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $2.48 | 159,056 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-29 7:21 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 160,056 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-29 7:21 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 160,056 (Direct) | View |
| 2025-01-07 Exercise | 2025-01-10 5:31 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 21,700 | $0 | 381,880 (Direct) | View |
| 2025-01-07 Exercise | 2025-01-10 5:31 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 10,700 | $1.12 | 381,880 (Direct) | View |
| 2025-01-07 Exercise | 2025-01-10 5:31 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 11,000 | $2.48 | 381,880 (Direct) | View |
| 2024-12-13 Exercise | 2025-01-07 4:43 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $0 | 318,862 (Direct) | View |
| 2024-12-13 Exercise | 2025-01-07 4:43 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $2.48 | 318,862 (Direct) | View |
| 2024-12-27 Exercise | 2024-12-31 5:18 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $0 | 329,512 (Direct) | View |
| 2024-12-27 Exercise | 2024-12-31 5:18 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $2.48 | 329,512 (Direct) | View |
| 2024-11-27 Exercise | 2024-12-02 5:18 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $0 | 168,556 (Direct) | View |
| 2024-11-27 Exercise | 2024-12-02 5:18 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $2.48 | 168,556 (Direct) | View |
| 2024-10-28 Exercise | 2024-10-30 6:04 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $0 | 173,806 (Direct) | View |
| 2024-10-28 Exercise | 2024-10-30 6:04 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $2.48 | 173,806 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:19 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 814 | $0 | 180,056 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:19 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 814 | $2.48 | 180,056 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:17 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $0 | 266,268 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:17 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $2.48 | 266,268 (Direct) | View |
| 2024-10-08 Exercise | 2024-10-10 8:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 6,314 | $19.68 | 104,091 (Direct) | View |
| 2024-10-08 Exercise | 2024-10-10 8:36 pm | N/A 2029-05-16 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 10,420 | $0 | 104,091 (Direct) | View |
| 2024-10-08 Exercise | 2024-10-10 8:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 4,106 | $5.52 | 104,091 (Direct) | View |
| 2024-10-04 Exercise | 2024-10-08 6:56 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 11,488 | $0 | 363,010 (Direct) | View |
| 2024-10-04 Exercise | 2024-10-08 6:56 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 11,488 | $2.48 | 363,010 (Direct) | View |